Point counterpoint in PCa screening
-
Upload
patricia-khashayar -
Category
Business
-
view
302 -
download
0
Transcript of Point counterpoint in PCa screening
![Page 1: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/1.jpg)
![Page 2: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/2.jpg)
G. Pourmand MD. Tehran University of Medical Sciences
May- June 2008
Point counterpoint: Prostate cancer in the elderly man:
Should we screen men after age 65 years?
![Page 3: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/3.jpg)
Yes No
Is prostate cancer a health care problem?
![Page 4: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/4.jpg)
Is cancer prevalence important?
Health planning
Benefits and Harms
Most are small, confined
![Page 5: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/5.jpg)
Cancer Incidence Rates * for Men US, 1973-1999
![Page 6: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/6.jpg)
When Does Screening Detect Cancer?
9 years before clinical presentation
![Page 7: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/7.jpg)
What about the prognosis?
Screen- Detected Prostate Cancer
• Conventionally Presenting Localized Disease
P.W. Nicholson, BJU International
2002,90,686-693
![Page 8: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/8.jpg)
To Screen or Not !
• Serious Public Problem.
• Asymp. Localized Phase
• Sensitivity, Specificity and Predictive Values
• The Potential for Cure
• Improved Outcomes Relation to Screen
![Page 9: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/9.jpg)
Cost- effectiveness
Avoid detecting biologically unimportant cancers
Detect and treat tumors Progress, Produce Symptoms and Reduce Life Expectancy
![Page 10: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/10.jpg)
American Cancer Society Modification
(Men who eligible for Pca Screening)
PSA and DRE AnnuallyShould or Offer?
![Page 11: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/11.jpg)
American Academy of Family
Physician And US Preventive Services Task Force
Do not Recommend Routine Screening in Low- Risk Patients
![Page 12: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/12.jpg)
National Screening 1996
Counseling Potential Harms Benefits Scientific Uncertainties
![Page 13: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/13.jpg)
Patient- Clinician Process
( Joint Decision Making)and
(Agree on a Course of Action)
![Page 14: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/14.jpg)
PSA and DRE from 50 years
Life expectancy of at least 10 years
Discussion
![Page 15: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/15.jpg)
PSA < 2 ng/ml Biannually
PSA ≥ 2 ng/ml Annually
![Page 16: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/16.jpg)
PSA (1980)
Most useful tumor marker
1- Detection 2- Monitoring • Radiation • Radical prostatectomy • Systemic therapy
![Page 17: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/17.jpg)
PSA
Glycoprotein
• Almost Exclusivelyin Prostate Epithelial Cells
![Page 18: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/18.jpg)
BPH
Prostatitis
Prostatic Infarction
Is PSA Ideal Tumor Marker?
![Page 19: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/19.jpg)
PSA thershold = 4 ng/mL:
65% F. Positive rate 20% F. Negative rate
PSA: 3 ng/mL Sensitivity Positive Predictive Value
![Page 20: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/20.jpg)
PSA Density
PSA Velocity
Age Specific Reference
May Increase Sensitivity and specificity
![Page 21: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/21.jpg)
Age Specific PSA, Reference Range
Age, yr Reference Range, ng/ml
40-49 …………………….. 0.0-2.5
50-59 …………………….. 0.0-3.5
60-69 …………………….. 0.0-4.5
70-79 …………………….. 0.0-6.5
![Page 22: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/22.jpg)
Use of PSA and PSA density to detect prostate cancer in men with normal DRE
PSA density(Threshold)
Sensitivity%
Specificity%
PositivePredictive Value
%
0.10 …………… 95 24 29
0.15 …………… 79 50 34
0.30 ……………. 45 85 50
0.50 ……………. 29 95 65
![Page 23: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/23.jpg)
Correlation Between PSA and Prostate Cancer
![Page 24: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/24.jpg)
Total PSA (ng/mL)PSA Density= Total prostate volume (mL)
![Page 25: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/25.jpg)
PSA Velocity
PSA ≥ 0.75 ng/mL
![Page 26: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/26.jpg)
Digital Rectal Examination
•Detect missed Pca by PSA Screening
• Able to detect asymptomatic patient
• Abnormal DRE (3.2%-10%)
• Pca (0.2%-1.7%) in original group
![Page 27: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/27.jpg)
ACS
DRE + Occult Blood >40 yrs
The (+ve) Predictive Value 17.8%
Sensitivity of DRE: 53.2%
Specificity of DRE: 83.6%
![Page 28: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/28.jpg)
Trans Rectal UltraSonography
Expensive
Not available for family physicians
Suffers from lack of specificity
![Page 29: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/29.jpg)
Biopsy
1- Elevated PSA + Benign DRE
TRUS
Visible abnormal lesions
2- Abnormal DRE + TRUS Regardless of PSA
![Page 30: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/30.jpg)
Charecteristics of Screening Tests
Test Sensitivity%
Specificity%
PositivePredictive Value
%
DRE 45-58 96-97 24-58
TRUS 71-91 89-94 15-43
PSA> 4 ng/ml
67-89 59-97 33-47
![Page 31: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/31.jpg)
![Page 32: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/32.jpg)
1 Andorra 83.53
2 Macau 82.35
….
47 United States 78.14
…
130 Iran 70.86
…
222 Angola 37.92
223 Swaziland 31.99
World’s Life expectancy report
![Page 33: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/33.jpg)
Population Pyramid for USA
![Page 34: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/34.jpg)
Population Pyramid for Iran
![Page 35: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/35.jpg)
1384:
2722
![Page 36: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/36.jpg)
Age-specific Incidence Rate of Prostate cancer per 100,000 Population in Iran (2005-2006)
Points
![Page 37: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/37.jpg)
• Prostate cancer screening remains widespread, despite recommendations against routine screening by the United States Preventive Services Task Force and the ACP, and recommendations by the AAFP for counseling about the known risks and uncertain benefits of screening for prostate cancer.
• Recent evidence shows that men older than 75 years are frequently screened for prostate cancer, despite current guidelines suggesting they are unlikely to benefit from treatment as the disease develops slowly in this age group.
Counterpoints
![Page 38: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/38.jpg)
Table shavad
• In a national surveys of physician-reported information carried out from 1999 to 2002 by Duke University Medical Center researchers:
Counterpoints (Cont.)
![Page 39: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/39.jpg)
• They concluded that
• Urologists were more likely to initiate the tests than non-urologists.
• Excessive PSA testing has direct and indirect costs, and reflects an inefficient allocation of resources.
Counterpoints (Cont.)
![Page 40: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/40.jpg)
• In another National Ambulatory Medical Care Surveys performed in 1995-6:
Counterpoints (Cont.)
![Page 41: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/41.jpg)
• High incidence of Pca in Iranian elderly men
- Ethical & moral values
• Short life following the detection
considering the life expectancy • Slow growing tumor• Death due to other
complications
Shall we screen elderly?
![Page 42: Point counterpoint in PCa screening](https://reader036.fdocuments.in/reader036/viewer/2022062514/558910d6d8b42ad7788b46f9/html5/thumbnails/42.jpg)